Table 1 Clinical, histopathological and survival data
From: Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients
Parameters | Total (n = 78) | relative LGR5FL mRNA-level ≤134.3 > 134.3 | relative LGR5Δ5 mRNA-level ≤2,9 > 2,9 | relative LGR5Δ8 mRNA-level ≤14.9 > 14.9 | relative LGR5all mRNA-level ≤8449.3 > 8449.3 | ||||
|---|---|---|---|---|---|---|---|---|---|
39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | ||
Gender | p = 0.15 | p = 0.15 | p = 0.15 | p = 0.15 | |||||
Male | 63 | 29 | 34 | 29 | 34 | 29 | 34 | 29 | 34 |
Female | 15 | 10 | 5 | 10 | 5 | 10 | 5 | 10 | 5 |
Tumor grade | p = 0.54 | p = 0.58 | p = 0.027* | p = 0.20 | |||||
I | 9 | 6 | 3 | 4 | 5 | 7 | 2 | 4 | 5 |
II | 57 | 27 | 30 | 30 | 27 | 29 | 28 | 32 | 25 |
III | 11 | 5 | 6 | 4 | 7 | 2 | 9 | 3 | 8 |
unknown | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
Tumor stage | p = 0.77 | p = 0.43 | p = 0.36 | p = 0.25 | |||||
I | 13 | 8 | 5 | 8 | 5 | 6 | 7 | 9 | 4 |
II | 25 | 13 | 12 | 14 | 11 | 12 | 13 | 11 | 14 |
III | 9 | 4 | 5 | 5 | 4 | 7 | 2 | 6 | 3 |
IV | 31 | 14 | 17 | 12 | 19 | 14 | 17 | 13 | 18 |
Patients at last follow-up | p = 0.48 | p = 0.035* | p = 0.81 | p = 0.48 | |||||
Alive | 29 | 16 | 13 | 19 | 10 | 14 | 15 | 16 | 13 |
Dead | 49 | 23 | 26 | 20 | 29 | 25 | 24 | 23 | 26 |
Recurrence | p = 0.289 | p = 0.933 | p = 0.289 | p = 0.464 | |||||
Yes | 25 | 15 | 10 | 13 | 12 | 15 | 10 | 14 | 11 |
No | 51 | 24 | 27 | 26 | 25 | 24 | 27 | 24 | 27 |
unknown | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 1 | 1 |
Lymph node status | p = 0.06 | p = 0.02* | p = 0.64 | p = 0.06 | |||||
N0 | 30 | 19 | 11 | 20 | 10 | 16 | 14 | 19 | 11 |
N1–3 | 48 | 20 | 28 | 19 | 29 | 23 | 25 | 20 | 28 |
Distant metastases | p = 0.3 | p = 0.3 | p = 0.3 | p = 1.0 | |||||
M0 | 74 | 38 | 36 | 38 | 36 | 36 | 38 | 37 | 37 |
M1 | 4 | 1 | 3 | 1 | 3 | 3 | 1 | 2 | 2 |
Survival analysis: Overall survival | |||||||||
Kaplan-Meier analysis | p = 0.21 | p = 0.004* | p = 0.88 | p = 0.063 | |||||
Median survival (months) | 27 | 17 | 42 | 14 | 25 | 19 | 42 | 15 | |
95% CI | 6.0–48.0 | 12.5–21.5 | 22.3–61.7 | 5.6–22.4 | 15.2–34.8 | 8.5–29.5 | 22.4–61.6 | 8–22.0 | |
Univariable Cox regression | p = 0.22 | p = 0.005* | p = 0.88 | p = 0.069 | |||||
Hazard ratio | 1.4 | 2.3 | 1.1 | 1.7 | |||||
95% CI | 0.8–2.5 | 1.3–4.0 | 0.6–1.8 | 0.9–3.0 | |||||
Multivariable Cox regression | p = 0.2 | p = 0.02* | p = 0.66 | p = 0.09 | |||||
Hazard ratio | 1.5 | 2.0 | 1.1 | 1.7 | |||||
95% CI | 0.8–2.7 | 1.1–3.7 | 0.6–2.1 | 0.9–3.0 | |||||
Survival analysis: Disease specific survival | |||||||||
Kaplan-Meier analysis | p = 0.22 | p = 0.001* | p = 0.40 | p = 0.018 | |||||
Median survival (months) | n.c. | 17 | n.c. | 14 | n.c. | 19 | n.c. | 15 | |
95% CI | 14.0–88 | 0–47 | 7.8–104 | 0.8–111 | |||||
Univariable Cox regression | p = 0.22 | p = 0.002* | p = 0.4 | p = 0.023* | |||||
Hazard ratio | 1.6 | 3.7 | 1.38 | 2.5 | |||||
95% CI | 0.75–3.4 | 1.6–8.6 | 0.65–2.95 | 1.13–5.5 | |||||
Multivariable Cox regression | p = 0.31 | p = 0.01* | p = 0.57 | p = 0.071 | |||||
Hazard ratio | 1.5 | 3.2 | 1.29 | 2.2 | |||||
95% CI | 0.67–3.6 | 1.3–8.0 | 0.54–3.1 | 0.94–5.0 | |||||